Literature DB >> 15982206

In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method.

Jagpal Singh1, Dagmar Rimek, Reinhard Kappe.   

Abstract

The in vitro susceptibility of 15 strains of six genera of zygomycetes including Rhizopus oryzae (Rhizopus arrhizus), Rhizopus stolonifer, Mucor circinelloides (three), Absidia corymbifera (three), Rhizomucor pusillus (three), Cunninghamella bertholletiae (two), and Syncephalastrum racemosum (two) to nine antifungal agents were determined by the NCCLS M38-A broth microdilution method. Geometric means of the minimal inhibitory concentrations (MIC) were: amphotericin B 0.07 mg l(-1) (range 0.03-0.5 mg l(-1)), nystatin 0.83 mg l(-1) (range 0.25-4 mg l(-1)), itraconazole 0.59 mg l(-1) (range 0.03 to >8 mg l(-1)), voriconazole 6.50 mg l(-1) (range 2 to >8 mg l(-1)), ciclopiroxolamine 1.59 mg l(-1) (range 0.5-4 mg l(-1)), and amorolfine 9.19 mg l(-1) (range 1 to >16 mg l(-1)). All strains were resistant to 5-flucytosine, fluconazole (MIC >64 mg l(-1)) and caspofungin (MIC >16 mg l(-1)).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982206     DOI: 10.1111/j.1439-0507.2005.01132.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  20 in total

1.  Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

Authors:  Ana Alastruey-Izquierdo; Isabel Cuesta; Grit Walther; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

2.  Mucor circinelloides was identified by molecular methods as a cause of primary cutaneous zygomycosis.

Authors:  Peter C Iwen; Lynne Sigler; Rhonda K Noel; Alison G Freifeld
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

3.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

4.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

Review 5.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

Review 6.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

7.  A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles.

Authors:  Lysett Wagner; Sybren de Hoog; Ana Alastruey-Izquierdo; Kerstin Voigt; Oliver Kurzai; Grit Walther
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

8.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

Review 9.  A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies.

Authors:  E Righi; C G Giacomazzi; V Lindstrom; A Albarello; O Soro; M Miglino; M Perotti; O E Varnier; M Gobbi; C Viscoli; M Bassetti
Journal:  Mycopathologia       Date:  2008-03-14       Impact factor: 2.574

10.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.